[go: up one dir, main page]

GB201105137D0 - Therapeutic molecules for use in the suppression of Parkinson's disease - Google Patents

Therapeutic molecules for use in the suppression of Parkinson's disease

Info

Publication number
GB201105137D0
GB201105137D0 GB201105137A GB201105137A GB201105137D0 GB 201105137 D0 GB201105137 D0 GB 201105137D0 GB 201105137 A GB201105137 A GB 201105137A GB 201105137 A GB201105137 A GB 201105137A GB 201105137 D0 GB201105137 D0 GB 201105137D0
Authority
GB
United Kingdom
Prior art keywords
parkinson
suppression
disease
therapeutic molecules
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201105137A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GB201105137A priority Critical patent/GB201105137D0/en
Publication of GB201105137D0 publication Critical patent/GB201105137D0/en
Priority to PCT/GB2012/050692 priority patent/WO2012131365A1/en
Ceased legal-status Critical Current

Links

GB201105137A 2011-03-28 2011-03-28 Therapeutic molecules for use in the suppression of Parkinson's disease Ceased GB201105137D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201105137A GB201105137D0 (en) 2011-03-28 2011-03-28 Therapeutic molecules for use in the suppression of Parkinson's disease
PCT/GB2012/050692 WO2012131365A1 (en) 2011-03-28 2012-03-28 Therapeutic molecules for use in the suppression of parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201105137A GB201105137D0 (en) 2011-03-28 2011-03-28 Therapeutic molecules for use in the suppression of Parkinson's disease

Publications (1)

Publication Number Publication Date
GB201105137D0 true GB201105137D0 (en) 2011-05-11

Family

ID=44067449

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201105137A Ceased GB201105137D0 (en) 2011-03-28 2011-03-28 Therapeutic molecules for use in the suppression of Parkinson's disease

Country Status (2)

Country Link
GB (1) GB201105137D0 (en)
WO (1) WO2012131365A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112400019A (en) * 2018-06-27 2021-02-23 Ionis制药公司 Compounds and methods for reducing LRRK2 expression

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014032913A2 (en) 2012-06-29 2017-06-27 Pfizer novel 4- (amino-substituted) -7h-pyrrolo [2,3-d] pyrimidines as lrrk2 inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
EP3377629B1 (en) 2015-11-18 2023-07-05 Rosalind Franklin University of Medicine and Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
US10370667B2 (en) 2015-11-18 2019-08-06 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
WO2017120365A1 (en) * 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
EP3724335A1 (en) * 2017-12-11 2020-10-21 Rosalind Franklin University of Medicine and Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
EP3833763A4 (en) * 2018-08-10 2023-07-19 University of Massachusetts MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
JP2022523467A (en) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ Anchors that modify dynamic pharmacokinetics
US11820985B2 (en) 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
BR112022002307A2 (en) * 2019-08-09 2022-06-28 Univ Massachusetts CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING SNPS
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
US12146136B2 (en) 2020-03-26 2024-11-19 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1105137A (en) 1964-04-06 1968-03-06 Chloride Overseas Ltd Improvements relating to fuel battery plants
EP1567539B1 (en) * 2002-11-04 2009-09-23 University of Massachusetts Allele-specific rna interference
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
WO2007124096A2 (en) * 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112400019A (en) * 2018-06-27 2021-02-23 Ionis制药公司 Compounds and methods for reducing LRRK2 expression
CN112400019B (en) * 2018-06-27 2024-05-07 Ionis制药公司 Compounds and methods for reducing LRRK2 expression

Also Published As

Publication number Publication date
WO2012131365A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL269511A (en) New therapeutic approaches to treat Parkinson's disease
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
PT3042910T (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
AP2014007601A0 (en) Novel purine derivatives and their use in the treatment of disease
ZA201403372B (en) Therapeutic agents and uses thereof
IL230957B (en) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
TWI559929B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
ZA201304822B (en) Azetidine derivatives useful for the treatment of metabolic and inflimmatory diseases
PL2726470T3 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
HRP20181950T1 (en) Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders
IL230441A0 (en) Diagnosis of alzheimer's disease
IL260078B (en) Therapy for use for the treatment of gaucher's disease
IL233572B (en) Fixed dose combination therapy of parkinson's disease
EP2709632A4 (en) Compositions and methods for the treatment of skin diseases
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
SG10201801200PA (en) An h3 receptor antagonist for use in the treatment of alzheimer's disease
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
IL239078A0 (en) Protein for use in the treatment of ocular diseases
HK1193342A (en) Pharmaceutical combination for use in the treatment of diabetes type 2
GB201113718D0 (en) Treatment of Dupuytren's Disease
HK1193975A (en) Cystamine analogues for the treatment of parkinson's disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)